Maushmi Sheth, MD
Clinical Neurophysiology · Frisco, TXNPI 1124221718
Payments from drug & device makers
Across 469 payments — averaging $353.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$116K
- Merz Pharmaceuticals, LLC$40K
- Biogen$3K
- AbbVie$2K
- Amgen$754
- Novartis$458
- plus $4K from 49 others
Across 1 payment — averaging $16,284 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$16K
What the payments were for
- Consulting fees$1,92019%
- Food & beverage$8,15381%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$165,962 in reported general payments places this provider in the 90th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 36 | $486,596 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 38 | $482,121 |
| NuplazidPimavanserin Tartrate | 37 | $180,318 |
| VumerityDiroximel Fumarate | 13 | $124,911 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $99,289 |
| CopaxoneGlatiramer Acetate | 11 | $64,152 |
| Nurtec OdtRimegepant Sulfate | 45 | $60,192 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $57,414 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $48,586 |
| Emgality PenGalcanezumab-Gnlm | 21 | $29,687 |
| QuliptaAtogepant | 19 | $26,208 |
| BriviactBrivaracetam | 11 | $25,465 |
| NeurontinGabapentin | 12 | $24,444 |
| Memantine Hcl | 911 | $21,506 |
| NayzilamMidazolam | 13 | $18,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Dilantin | $150 | $550,45796 claims |
| Kedrion Biopharma, Inc.Gammaked | $24 | $482,12138 claims |
| Acadia Pharmaceuticals IncNuplazid | $270 | $180,31837 claims |
| BiogenVumerity | $2,786 | $124,91113 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $167 | $64,15211 claims |
| UCB, Inc.Briviact, Nayzilam, Neupro | $74 | $58,76035 claims |
| AbbVieQulipta, Ubrelvy | $2,014 | $42,97735 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $23 | $23,10266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 50 clinical neurophysiology providers in Texas.
Other clinical neurophysiology in Frisco
- Steffani HerreraFrisco$384
- Mark GilbertHouston$3.6M
- Hina DaveHouston$245K
- Adam SheffieldDallas$211K
- Thy NguyenHouston$198K
- Nora Vanegas ArroyaveHouston$109K
- Omotola HopeHouston$83K
- Samden LhatooHouston$66K
- Kalarickal OommenLubbock$59K
- Monika UmmatHouston$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.